NC PTA Balloon Dilatation Catheter
Kossel Medtech (Suzhou) Co., Ltd. · Decision date Sep 16, 2026
What did the FDA decide?
On September 16, 2026, FDA recorded a substantially equivalent (SESE) decision for the NC PTA Balloon Dilatation Catheter submitted by Kossel Medtech (Suzhou) Co., Ltd. under K254212, product code LIT, cardiovascular specialty. The document states the device is indicated for percutaneous transluminal angioplasty of the peripheral vasculature. The catheter is described as a two-lumen design, with one lumen used for balloon inflation and deflation.
The decision letter states that differences between the subject device and the predicate and reference devices do not raise new questions of safety or effectiveness. The excerpts also reference the Maxi Diameter Balloon PTA Dilatation Catheter and the Atlas Gold PTA Dilatation Catheter as comparator devices. The source does not provide the full indications text, the complete predicate list, or the basis for the equivalence finding, so those details remain unknown from this record.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 16, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K254212
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Kossel Medtech (Suzhou) Co., Ltd.
- Product code
- LIT
- Decision code
- SESE
- Decision date
- Sep 16, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Catheter, Angioplasty, Peripheral, Transluminal.
- Applicant
- Kossel Medtech (Suzhou) Co., Ltd.
- Product code
- LIT
- FDA device class
- 2
FDA decision timeline
K254212 received
Application receipt date recorded by FDA.
K254212 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code LIT
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Brosmed Medical Co., Ltd. | 510(k) clearance | Nov 2, 2026 | FDA | |
| Zylox Medtech Co., Ltd. | 510(k) clearance | Sep 21, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Kossel Medtech (Suzhou) Co., Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Suzhou New District
Sources and methodology
- Original FDA record: K254212
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records